Multicellular gastric cancer spheroids represent a valid model for pre-clinical testing of new therapeutic strategies

2001 ◽  
Vol 37 ◽  
pp. S11
Author(s):  
B. Mayer ◽  
G. Klement ◽  
M. Kaneko ◽  
S. Jothy ◽  
R.S. Kerbel
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Strategies ◽  
Clinical Testing ◽  
Valid Model ◽  
Cancer Spheroids

scholarly journals Personalized therapeutic strategies in HER2-driven gastric cancer

2021 ◽  
Author(s):  
Stefano Ughetto ◽  
Cristina Migliore ◽  
Filippo Pietrantonio ◽  
Maria Apicella ◽  
Annalisa Petrelli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Strategies

scholarly journals Immune evasion mechanisms and therapeutic strategies in gastric cancer

2022 ◽  
Vol 14 (1) ◽  
pp. 216-229
Author(s):  
En-Si Ma ◽  
Zheng-Xin Wang ◽  
Meng-Qi Zhu ◽  
Jing Zhao
Keyword(s):  
Gastric Cancer ◽  
Immune Evasion ◽  
Therapeutic Strategies

Real-world fusion landscape in advanced Chinese gastric cancer using next generation sequencing: A multicenter study.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 51-51
Author(s):  
Rongbo Lin ◽  
Shen Zhao ◽  
Lisheng Cai ◽  
Shaoqin Chen ◽  
Jinhuo Lai ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Next Generation Sequencing ◽  
Multicenter Study ◽  
Index Patient ◽  
Therapeutic Strategies ◽  
Next Generation ◽  
Entire Cohort ◽  
Next Generation Sequencing Ngs ◽  
Disease Cell ◽  
Generation Sequencing

51 Background: Gastric cancer (GC) is a highly heterogeneous disease. Cell-free DNA (cfDNA) has been a research hotspot in molecular tumor profiling. In advanced GC patients, malignant pleural effusion (MPE) and ascites provide a wealth of tumor cells that can be investigated. The aim of this study is to investigate fusion landscape in advanced GC. Methods: A multicenter study in China was initiated from Aug. 2016, and GC patients have been enrolled as of Aug. 2018. To determine the fusion frequency in GC, we analyzed data from 371clinical GC cases, each of which had results from next-generation sequencing (NGS)-based 381 genes panel assay, analogous to the index patient. Results: Of this entire cohort, 61 patients (16.44%) were identified with fusions, including TMEM45B-FGF3 (3), AXIN1-SMPD3 (3), B3GNTL1-ERBB2 (2), ERBB2-LAMA3 (2), ERBB2-ACLY (2), TRIM24-BRAF (2), ARHGEF1-CD79A (2), FGFR4-UIMC1 (2), MSH2-TTC7A (2), SMARCA4-LDLR (2), GON4L-RIT1 (2), AKT1-CPSF2 (2), GATA6-COLEC12 (2), RICTOR-EFNA5 (2), KAT6A-PLAT (2), ROCK1-CCDC178 (2), HBS1L-MYB (2), SLC30A2-ARID1A (2), MSI2-BIRC5 (2), NOTCH3-UCA1 (2), PIK3C2B-KISS1 (2), RICTOR-OSMR (2), FGFR2-MIR5694 (2), FGFR2-FGFR1 (2), MAN2A2-BLM (2), EGFR-MED15 (1), EML4-ALK(1), GOPC-ROS1 (1), FXR2-TP53 (1), NF1-PSMD11 (1), IRS2-PRKCI (1), FGFR2-KIAA1217(1), FGFR2-TACC2 (1), FGFR3-TACC3 (1). ERBB2, BRAF, EGFR, ALK and ROS1 fusionswere seen in 18.03% (11/61) of advanced Chinese gastric cancer fusion landscape patients. Conclusions: Advanced Chinese gastric cancer fusion landscape is rich, ERBB2, BRAF, EGFR, ALK and ROS1 fusions are rare but potentially druggable in TKIs. Detection of ERBB2, BRAF, EGFR, ALK and ROS1 fusions should be part of comprehensive profiling panels to determine TKIs and direct appropriate combination therapeutic strategies.

Diagnostic and therapeutic strategies for gastric cancer in the era of precision medicine

2017 ◽  
Vol 1 ◽  
pp. 1-1
Author(s):  
Kecheng Zhang ◽  
Xiaohui Huang ◽  
Bo Wei ◽  
Xiaosong Wu ◽  
Hongqing Xi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Precision Medicine ◽  
Therapeutic Strategies

MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer

2010 ◽  
Vol 297 (2) ◽  
pp. 137-143 ◽  
Author(s):  
Jianbo Wang ◽  
Qingwei Wang ◽  
Hong Liu ◽  
Bo Hu ◽  
Wei Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Strategies ◽  
Microrna Expression

scholarly journals Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiao-Jiang Chen ◽  
Guo-Ming Chen ◽  
Yi-Cheng Wei ◽  
Hong Yu ◽  
Xi-Cheng Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Propensity Score ◽  
Advanced Gastric Cancer ◽  
Propensity Score Matching ◽  
Protective Factor ◽  
Late Complication ◽  
Outlet Obstruction ◽  
Therapeutic Strategies ◽  
Complication Rates ◽  
Palliative Gastrectomy

Abstract Background Gastric outlet obstruction (GOO) is a late complication of advanced gastric cancer, and it is controversial how to select the therapeutic strategies: gastrojejunostomy and palliative gastrectomy? Therefore, this study was to compare the surgical and survival outcomes of gastrojejunostomy and palliative gastrectomy. Methods In total, 199 gastric cancer patients with outlet obstruction treated by surgery between January 2000 and December 2015 at Sun Yat-sen University Cancer Center were retrospectively reviewed. Patients were divided into gastrojejunostomy group and palliative gastrectomy group. Propensity score matching (PSM) was performed to balance the selection bias. Results After 1:1 PSM, a total of 104 patients were included for final analysis. The median overall survival (OS) times in the gastrojejunostomy group and palliative gastrectomy group were 8.50 and 11.87 months, respectively (P = 0.243). The postoperative complication rates in the gastrojejunostomy group and palliative gastrectomy group were 19.23% (10/52) and 17.31% (9/52), respectively (P = 0.800), and no treatment-related death was observed. Multivariate analysis showed that periton0eal seeding (P = 0.014) and chemotherapy (P < 0.001) were independent prognostic factors. Among them, peritoneal seeding was a risk factor and postoperative chemotherapy was a protective factor. Conclusions Our results indicated that although the surgical complications of palliative gastrectomy were manageable, it showed no survival benefit. Therefore, relieving obstruction symptom, improving patients’ quality of life and creating better conditions for chemotherapy appear to be the main therapeutic strategies for advanced gastric cancer with GOO.

scholarly journals β-Galactosidase is a target enzyme for detecting peritoneal metastasis of gastric cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hidemasa Kubo ◽  
Yasutoshi Murayama ◽  
Soichiro Ogawa ◽  
Tatsuya Matsumoto ◽  
Masayuki Yubakami ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cell Lines ◽  
Peritoneal Metastasis ◽  
Therapeutic Strategies ◽  
Fluorescence Probes ◽  
Gamma Glutamyl Transpeptidase ◽  
Key Enzyme ◽  
High Fluorescence ◽  
Glutamyl Transpeptidase ◽  
Target Enzyme

AbstractDiagnosis of peritoneal metastasis in gastric cancer (GC) is essential for determining appropriate therapeutic strategies and avoiding non-essential laparotomy or gastrectomy. Recently, a variety of activatable fluorescence probes that can detect enzyme activities have been developed for cancer imaging. The aim of this study was to identify the key enzyme involved in peritoneal metastasis in GC. The enzymatic activity of gamma-glutamyl transpeptidase, dipeptidyl peptidase IV, and β-galactosidase (β-Gal) was assessed in lysates prepared from preserved human GC (n = 89) and normal peritoneal (NP; n = 20) samples. β-Gal activity was significantly higher in the human GC samples than in NP samples, whereas no differences were observed in the activities of the other enzymes. Therefore, we used SPiDER-βGal, a fluorescent probe that can be activated by β-Gal, for imaging GC cell lines, peritoneal metastasis in a mouse model, and fresh human resected GC samples (n = 13). All cell lines showed fluorescence after applying SPiDER-βGal, and metastatic nodules in the mice gradually developed high fluorescence that could be visualized with SPiDER-βGal. The human GC samples showed significantly higher fluorescence than NP samples. β-Gal is a useful target enzyme for fluorescence imaging of peritoneal metastasis in GC.

scholarly journals Hereditary Diffuse Gastric Cancer: A Comparative Cohort Study According to Pathogenic Variant Status

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3726
Author(s):  
Tim Marwitz ◽  
Robert Hüneburg ◽  
Isabel Spier ◽  
Jan-Frederic Lau ◽  
Glen Kristiansen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cohort Study ◽  
Detection Rate ◽  
Cancer Susceptibility ◽  
Hereditary Diffuse Gastric Cancer ◽  
Diffuse Gastric Cancer ◽  
Clinical Testing ◽  
Inherited Cancer ◽  
Germline Variant ◽  
Testing Criteria

Hereditary diffuse gastric cancer (HDGC) is an inherited cancer susceptibility syndrome characterized by an elevated risk for diffuse gastric cancer (DGC) and lobular breast cancer (LBC). Some patients fulfilling the clinical testing criteria harbor a pathogenic CDH1 or CTNNA1 germline variant. However, the underlying mechanism for around 80% of the patients with a family or personal history of DGC and LBC has so far not been elucidated. In this cohort study, patients meeting the 2015 HDGC clinical testing criteria were included, and subsequently, CDH1 sequencing was performed. Of the 207 patients (161 families) in this study, we detected 21 pathogenic or likely pathogenic CDH1 variants (PV) in 60 patients (28 families) and one CTNNA1 PV in two patients from one family. Sixty-eight percent (n = 141) of patients were female. The overall PV detection rate was 18% (29/161 families). Criterion 1 and 3 of the 2015 HDGC testing criteria yielded the highest detection rate of CDH1/CTNNA1 PVs (21% and 28%). PV carriers and patients without proven PV were compared. Risk of gastric cancer (GC) (38/62 61% vs. 102/140 73%) and age at diagnosis (40 ± 13 years vs. 44 ± 12 years) were similar between the two groups. However, GC was more advanced in gastrectomy specimens of patients without PV (81% vs. 26%). LBC prevalence in female carriers of a PV was 20% (n = 8/40). Clinical phenotypes differed strongly between families with the same PV. Emphasis should be on detecting more causative genes predisposing for HDGC and improve the management of patients without a proven pathogenic germline variant.

scholarly journals Multicellular Human Gastric Cancer Spheroids Mimic the Glycosylation Phenotype of Gastric Carcinomas

Molecules ◽  
2018 ◽  
Vol 23 (11) ◽  
pp. 2815 ◽  
Author(s):  
Meritxell Balmaña ◽  
Stefan Mereiter ◽  
Francisca Diniz ◽  
Tália Feijão ◽  
Cristina Barrias ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Molecular Mechanisms ◽  
3D Cell Culture ◽  
Automated Image Analysis ◽  
Human Gastric Cancer ◽  
Gastric Cancer Cells ◽  
Model Cell ◽  
Cancer Spheroids ◽  
The Impact

Cellular glycosylation plays a pivotal role in several molecular mechanisms controlling cell–cell recognition, communication, and adhesion. Thus, aberrant glycosylation has a major impact on the acquisition of malignant features in the tumor progression of patients. To mimic these in vivo features, an innovative high-throughput 3D spheroid culture methodology has been developed for gastric cancer cells. The assessment of cancer cell spheroids’ physical characteristics, such as size, morphology and solidity, as well as the impact of glycosylation inhibitors on spheroid formation was performed applying automated image analysis. A detailed evaluation of key glycans and glycoproteins displayed by the gastric cancer spheroids and their counterpart cells cultured under conventional 2D conditions was performed. Our results show that, by applying 3D cell culture approaches, the model cell lines represented the differentiation features observed in the original tumors and the cellular glycocalix underwent striking changes, displaying increased expression of cancer-associated glycan antigens and mucin MUC1, ultimately better simulating the glycosylation phenotype of the gastric tumor.

Sign in / Sign up

Export Citation Format

Share Document